Status:
ACTIVE_NOT_RECRUITING
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
American Cancer Society, Inc.
Conditions:
Cancer
Genetic Predisposition
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and ...
Detailed Description
As clinical practice increasingly use multi-gene testing, many patients are left with unknowns after genetic testing. Many have results that are unclear and may or may not be associated with any risk ...
Eligibility Criteria
Inclusion
- 18 years of age or older
- English Speaking
- Male or Female
- Internet and/or mobile access
- Previously received clinical genetic counseling and testing for hereditary cancer syndromes (up to 60 days prior to recruitment)
Exclusion
- •No internet and/or mobile access
Key Trial Info
Start Date :
May 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04774445
Start Date
May 3 2021
End Date
April 1 2026
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104